Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Cabozantinib + Nivolumab + Ipilimumab for Thyroid Cancer
Recruiting1 awardPhase 2
Olathe, Kansas
This trial studies how well a combination of cabozantinib, nivolumab, and ipilimumab works in patients with thyroid cancer that hasn't responded to other treatments. Cabozantinib stops cancer growth by blocking certain enzymes, while nivolumab and ipilimumab help the immune system fight the cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service